Literature DB >> 12866377

Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.

Neal S Goldstein1, Monica Ferkowicz, Eva Odish, Anju Mani, Farnaz Hastah.   

Abstract

To identify the minimum time necessary for consistent immunohistochemical estrogen receptor (ER) results in our laboratory, we evaluated results in timed fixation blocks and cases with disparate and similar needle core biopsy and partial mastectomy specimens. Tissue sections of 24 ER-positive, invasive breast carcinomas were fixed for 3, 6, 8, and 12 hours and 1, 2, and 7 days. ER values were quantified using the Q score (0-7). In timed fixation blocks, the mean Q score per block was 2.46 for blocks fixed for 3 hours, 5.75 for blocks fixed for 6 hours, and 6.70 for blocks fixed for 8 hours (P < .001). The difference between the case maximum and mean block Q scores was a plateau of almost 0 at 6 to 8 hours of formalin fixation. For needle core biopsy specimen fixation times, the means for specimens with ER-disparate and ER-similar results were 1.2 and 6.3 hours, respectively (P = .01). The minimum formalin fixation time for reliable immunohistochemical ER results is 6 to 8 hours in our laboratory, regardless of the type or size of specimen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866377     DOI: 10.1309/QPHD-RB00-QXGM-UQ9N

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  53 in total

1.  Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.

Authors:  Lajos Pusztai; Giuseppe Viale; Catherine M Kelly; Clifford A Hudis
Journal:  Oncologist       Date:  2010-11-01

2.  The effect of freezing on the immunoprofile of breast carcinoma cells.

Authors:  Asuman Argon; Alper Şener; Osman Zekioğlu; Murat Kapkaç; Necmettin Özdemir
Journal:  Balkan Med J       Date:  2014-12-01       Impact factor: 2.021

Review 3.  The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.

Authors:  Zsolt Hodi; Jayeta Chakrabarti; Andrew H S Lee; John E Ronan; Christopher W Elston; Kwok Leung Cheung; John F R Robertson; Ian O Ellis
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

4.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  Arch Pathol Lab Med       Date:  2010-06       Impact factor: 5.534

5.  The use of mouse models of breast cancer and quantitative image analysis to evaluate hormone receptor antigenicity after microwave-assisted formalin fixation.

Authors:  Jesse A Engelberg; Richard T Giberson; Lawrence J T Young; Neil E Hubbard; Robert D Cardiff
Journal:  J Histochem Cytochem       Date:  2014-03-28       Impact factor: 2.479

Review 6.  The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?

Authors:  Mustafa Khasraw; Edi Brogi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

7.  Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations.

Authors:  Sharenda L Williams; George G Birdsong; Cynthia Cohen; Momin T Siddiqui
Journal:  Int J Clin Exp Pathol       Date:  2009-01-20

8.  Validation of tissue microarray technology in ovarian cancer: results from the Nurses' Health Study.

Authors:  Jonathan L Hecht; Joanne Kotsopoulos; Margaret A Gates; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

9.  Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?

Authors:  Dominique Sighoko; Juxin Liu; Ningqi Hou; Paul Gustafson; Dezheng Huo
Journal:  Oncologist       Date:  2014-05-07

10.  Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Jacob J Kennedy; Jeffrey R Whiteaker; Regine M Schoenherr; Ping Yan; Kimberly Allison; Melissa Shipley; Melissa Lerch; Andrew N Hoofnagle; Geoffrey Stuart Baird; Amanda G Paulovich
Journal:  J Proteome Res       Date:  2016-07-27       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.